3 Plaintiffs File New Zantac Cancer Lawsuits
Three brand new plaintiffs have been added to the growing pile of Zantac Lawsuits. Two of them being filed in federal court in Connecticut. These lawsuits will be sent to the Southern District of Florida where all federally filed Zantac Lawsuits were recently centralized for pre-trial proceedings. They blame the manufacturer for failing to warn about the risks associated with their acid-reducing drug.
The first plaintiff is a resident of Kentucky. He began taking Zantac in the year 2000 and continued to take it through 2018. He claims that as a result of his exposure to Zantac, he was diagnosed with esophageal cancer. He blames his diagnosis on his exposure to Zantac because it has been found to contain N-nitrosodimethylamine (NDMA), a cancer-causing agent. Had he known that the medication contained NDMA, he says he never would have taken it. He has suffered pain and loss of enjoyment of life as a result of his injuries and has also lost earnings and earning capacity.
The second plaintiff is a resident of Iowa. She purchased and ingested Zantac between 2009 and 2015. She claims that as a result of using the drug, she was diagnosed with breast cancer. According to her complaint, she incurred and will continue to incur expenses in connection with medical treatment, and has suffered lost earnings and loss of earning capacity.
Both plaintiffs believe that their intake of Zantac caused their cancer, and seek to hold the manufacturers liable for their injuries.
FDA Announces Voluntary Recall Of Ranitidine Capsules
The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc., used to decrease the amount of acid created by the stomach. This recall is due to a nitrosamine impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled medicine. NDMA is classified as a probable human carcinogen (a substance that could cause cancer).
“The FDA is committed to ensuring that the medicines Americans take are safe and effective. We began testing ranitidine products immediately after we learned of the potential impurity. When we identify lapses in the quality of drugs that pose potential risks for patients, the FDA makes all efforts to understand the issue and provide our best recommendation to the public as quickly and accurately as possible,” said Acting FDA Commissioner Ned Sharpless, M.D. “We will continue to investigate and work to ensure these types of impurities do not exceed acceptable limits, so that patients can continue taking the medicines they need without concern.”
Zantac lawsuits are currently being compiled for litigation and potential compensation. If you or a loved one were diagnosed with cancer after taking Zantac or other Generic ranitidine products you may be entitled to compensation. Contact us for more information.